Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis

Joan Cid1, Reyes Aguinaco, Rafael Sánchez

  • 1Haematology Service, Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain. jcid.hj23.ics@gencat.cat

Abstract

Insights

CD64 expression on polymorphonuclear neutrophils (PMN) shows promise as a diagnostic marker for bacterial infections, with high pooled sensitivity and specificity. However, the overall methodological quality of existing studies is low.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Diagnostic Accuracy

Background:

  • Bacterial infections pose a significant global health challenge.
  • Accurate and timely diagnosis is crucial for effective treatment.
  • Novel diagnostic markers are continuously being investigated.

Purpose of the Study:

  • To systematically review and meta-analyze studies evaluating CD64 expression on polymorphonuclear neutrophils (PMN) as a diagnostic marker for bacterial infections.
  • To assess the diagnostic accuracy, including sensitivity and specificity, of CD64 expression in identifying bacterial infections across diverse patient populations.

Main Methods:

  • Systematic review and meta-analysis of prospective studies.
  • Inclusion of patients from all age groups.
  • Evaluation of study quality using STARD criteria.
  • Calculation of pooled sensitivity, specificity, and summary receiver operating characteristic (SROC) curve.

Main Results:

  • Thirteen studies were included, with methodological quality scores ranging from 9 to 16 (maximum 25).
  • Pooled sensitivity for CD64 expression on PMNs was 79% (95% CI: 70-86%).
  • Pooled specificity was 91% (95% CI: 85-95%), with an area under the curve (AUC) of 0.94.

Conclusions:

  • CD64 expression on PMNs demonstrates potential as a valuable cell-based diagnostic parameter for bacterial infections.
  • Despite promising accuracy, the published studies exhibit low methodological quality, necessitating further high-quality research.
  • Future studies should focus on improving methodological rigor to confirm the clinical utility of CD64 as a biomarker.

Related Concept Videos